

Francesco Ceci

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2291616/francesco-ceci-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92
papers

2,520
citations

25
h-index

48
g-index

129
ext. papers

3,245
ext. citations

4.7
avg, IF

5.03
L-index

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 92 | Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 1014-1024 | 8.8 | 399 |
| 91 | F-fluciclovine PET-CT and Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1286-1294 | 21.7 | 209 |
| 90 | (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 1284-94 | 8.8 | 204 |
| 89 | Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 230-237 | 8.9 | 164 |
| 88 | Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1424-9 | 8.9 | 104 |
| 87 | Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 2222-31 | 8.8 | 76 |
| 86 | (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1971-9 | 8.8 | 68 |
| 85 | (11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 84-91 | 8.8 | 68 |
| 84 | Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA . <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 11-19 | 8.8 | 67 |
| 83 | Potential Impact of Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1714-1721 | 8.9 | 64 |
| 82 | Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 1622-1635 | 8.8 | 59 |
| 81 | The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level . <i>Clinical Nuclear Medicine</i> , 2013 , 38, e342-5 | 1.7 | 58 |
| 80 | Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 31-39 | 8.8 | 55 |
| 79 | Comparison of Ga-PSMA-11 and F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 789-794 | 8.9 | 54 |
| 78 | E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 1626-1638 | 8.8 | 50 |
| 77 | 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 878-86 | 8.8 | 46 |
| 76 | (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 149-55 | 8.8 | 42 |

| | | | |
|----|---|------|----|
| 75 | Prediction nomogram for Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 136-146 | 8.8 | 38 |
| 74 | F-Fluorodeoxyglucose Uptake in Patient With Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019) Referred to Positron Emission Tomography/Computed Tomography for NSCLC Restaging. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1078-1080 | 8.9 | 37 |
| 73 | F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival. <i>Cancers</i> , 2020 , 12, | 6.6 | 36 |
| 72 | 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer. <i>Clinical Nuclear Medicine</i> , 2015 , 40, e265-70 | 1.7 | 35 |
| 71 | Diagnostic accuracy of (11)C-choline PET/CT in preoperative lymph node staging of bladder cancer: a systematic comparison with contrast-enhanced CT and histologic findings. <i>Clinical Nuclear Medicine</i> , 2014 , 39, e308-12 | 1.7 | 33 |
| 70 | 11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 43S-48S | 8.9 | 32 |
| 69 | 11C-choline PET/CT and bladder cancer: lymph node metastasis assessment with pathological specimens as reference standard. <i>Clinical Nuclear Medicine</i> , 2015 , 40, e124-8 | 1.7 | 27 |
| 68 | Therapy assessment in prostate cancer using choline and PSMA PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 78-83 | 8.8 | 25 |
| 67 | Restaging clear cell renal carcinoma with 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2014 , 39, e320-4 | 1.7 | 25 |
| 66 | The role of F-FDG PET/CT in the detection of osteosarcoma recurrence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 1712-1720 | 8.8 | 20 |
| 65 | Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 49S-54S | 8.9 | 20 |
| 64 | Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. <i>JAMA Oncology</i> , 2021 , 7, 1635-1642 | 13.4 | 20 |
| 63 | 11C-choline PET/CT for restaging of bladder cancer. <i>Clinical Nuclear Medicine</i> , 2015 , 40, e1-5 | 1.7 | 19 |
| 62 | The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques?. <i>Current Radiopharmaceuticals</i> , 2013 , 6, 92-5 | 1.8 | 19 |
| 61 | New aspects of molecular imaging in prostate cancer. <i>Methods</i> , 2017 , 130, 36-41 | 4.6 | 16 |
| 60 | Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 63, 7-18 | 1.4 | 15 |
| 59 | Predictive accuracy and clinical benefit of a nomogram aimed to predict Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA . <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 2100-2105 | 8.8 | 13 |
| 58 | 11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: a sequential PET/CT study. <i>Clinical Nuclear Medicine</i> , 2013 , 38, e279-82 | 1.7 | 13 |

| | | | |
|----|---|-----|----|
| 57 | How does Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?. <i>International Journal of Urology</i> , 2019 , 26, 804-811 | 2.3 | 12 |
| 56 | (68)Ga-PSMA-PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse After Radical Prostatectomy for Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e415-7 | 3.3 | 12 |
| 55 | Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase III imaging study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5502-5502 | 2.2 | 12 |
| 54 | Choline PET/CT features to predict survival outcome in high risk prostate cancer restaging: a preliminary machine-learning radiomics study. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , | 1.4 | 12 |
| 53 | Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review. <i>European Urology Oncology</i> , 2020 , 3, 565-581 | 6.7 | 12 |
| 52 | State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer. <i>International Journal of Urology</i> , 2019 , 26, 18-30 | 2.3 | 12 |
| 51 | Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 2804-2815 | 8.8 | 12 |
| 50 | State of the art of PET/CT with 11-choline and 18F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer. <i>Archivos Espanoles De Urologia</i> , 2015 , 68, 354-70 | 0.4 | 12 |
| 49 | Preoperative Staging With C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 305-312.e1 | 3.3 | 11 |
| 48 | Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row : Nodal oligorecurrent prostate cancer. <i>World Journal of Urology</i> , 2019 , 37, 2607-2613 | 4 | 10 |
| 47 | A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?. <i>European Urology Oncology</i> , 2021 , 4, 745-754 | 6.7 | 10 |
| 46 | First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection. <i>Archivio Italiano Di Urologia Andrologia</i> , 2014 , 86, 239-40 | 1.6 | 8 |
| 45 | Reply: Comparison of Ga-PSMA-11 and F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective Trial Is on Its Way. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 861 | 8.9 | 7 |
| 44 | Imaging of Prostate Cancer Using C-Choline PET/Computed Tomography. <i>Urologic Clinics of North America</i> , 2018 , 45, 481-487 | 2.9 | 7 |
| 43 | Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 3925-3939 | 8.8 | 7 |
| 42 | Male Breast Cancer Detected by Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 154-156 | 3.3 | 6 |
| 41 | Prospective head-to-head comparison of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT for localization of prostate cancer biochemical recurrence after primary prostatectomy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 15-15 | 2.2 | 6 |
| 40 | Detection of Sarcomatoid Lung Metastasis With 68GA-PSMA PET/CT in a Patient With Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016 , 41, 421-2 | 1.7 | 6 |

| | | | |
|----|---|------|---|
| 39 | Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 751-758 | 8.8 | 6 |
| 38 | PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer. <i>PET Clinics</i> , 2015 , 10, 487-94 | 2.2 | 5 |
| 37 | Ga-PSMA PET/CT in prostate cancer. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2018 , 37, 130-138 | 0.4 | 5 |
| 36 | Molecular Imaging and Precision Medicine in Prostate Cancer. <i>PET Clinics</i> , 2017 , 12, 83-92 | 2.2 | 5 |
| 35 | Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence.. <i>European Urology Oncology</i> , 2021 , | 6.7 | 5 |
| 34 | Health technology assessment for PSMA-PET: striving towards a cost-effective management of prostate cancer. <i>Clinical and Translational Imaging</i> , 2021 , 9, 409-412 | 2 | 5 |
| 33 | A New Type of Prostate Cancer Imaging: Will CuCl PET/CT Flourish or Vanish?.. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 442-443 | 8.9 | 5 |
| 32 | Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359221081922 | 5.4 | 5 |
| 31 | What is the best PET target for early biochemical recurrence of prostate cancer?-AuthorsUreply. <i>Lancet Oncology, The</i> , 2019 , 20, e609-e610 | 21.7 | 4 |
| 30 | [F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. <i>EJNMMI Research</i> , 2020 , 10, 122 | 3.6 | 4 |
| 29 | Future Perspective of the Application of Positron Emission Tomography-Computed Tomography-MR Imaging in Musculoskeletal Disorders. <i>PET Clinics</i> , 2019 , 14, 183-191 | 2.2 | 4 |
| 28 | Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by Ga-PSMA-11 PET/CT. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e53-e55 | 3.3 | 4 |
| 27 | Impact of segmentation and discretization on radiomic features in Ga-DOTA-TOC PET/CT images of neuroendocrine tumor. <i>EJNMMI Physics</i> , 2021 , 8, 21 | 4.4 | 4 |
| 26 | 18F-Fluciclovine Positron Emission Tomography in Prostate Cancer: A Systematic Review and Diagnostic Meta-Analysis. <i>Diagnostics</i> , 2021 , 11, | 3.8 | 4 |
| 25 | A Rare Case of Epididymal Metastasis After Radical Prostatectomy Detected by 68Ga-PSMA PET/CT. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e525-e527 | 3.3 | 3 |
| 24 | Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2013 , 32, 310-3 | 0.4 | 3 |
| 23 | Ga-DOTATOC PET/CT-Based Radiomic Analysis and PRRT Outcome: A Preliminary Evaluation Based on an Exploratory Radiomic Analysis on Two Patients. <i>Frontiers in Medicine</i> , 2020 , 7, 601853 | 4.9 | 3 |
| 22 | Event-free survival after [Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022 , 1 | 8.8 | 3 |

| | | | |
|----|---|-----|---|
| 21 | Imaging of Prostate Cancer Using C-Choline PET/Computed Tomography. <i>PET Clinics</i> , 2017 , 12, 137-143 | 2.2 | 2 |
| 20 | PET/CT in prostate cancer. <i>Medecine Nucleaire</i> , 2015 , 39, 54-58 | 0.1 | 2 |
| 19 | Incidental Detection of Basaloid Thymic Carcinoma With Ga-PSMA-11 PET/CT in a Patient With Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e497-e499 | 3.3 | 2 |
| 18 | 68Ga-Prostate-Specific Membrane Antigen 11 PET/CT Detects Residual Glioblastoma After Radical Surgery in a Patient With Synchronous Recurrent Prostate Cancer: A Case Report. <i>Clinical Nuclear Medicine</i> , 2020 , 45, e151-e153 | 1.7 | 2 |
| 17 | Clinical application of Fluciclovine PET, choline PET and gastrin-releasing polypeptide receptor (bombesin) targeting PET in prostate cancer. <i>Current Opinion in Urology</i> , 2020 , 30, 641-648 | 2.8 | 2 |
| 16 | Diagnostic Value of Conventional PET Parameters and Radiomic Features Extracted from 18F-FDG-PET/CT for Histologic Subtype Classification and Characterization of Lung Neuroendocrine Neoplasms. <i>Biomedicines</i> , 2021 , 9, | 4.8 | 2 |
| 15 | Focal Therapy for Prostate Cancer: Complications and Their Treatment. <i>Frontiers in Surgery</i> , 2021 , 8, 6962-6972 | 2.4 | 2 |
| 14 | Lung uptake detected by Ga-PSMA-11 PET/CT in prostate cancer patients with SARS-CoV-2: a case series. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 11, 300-306 | 2.2 | 1 |
| 13 | Prostate-specific Membrane Antigen Positron Emission Tomography, Not Conventional Imaging, Should Be Performed for Primary Staging of High-risk Prostate Cancer. <i>European Urology Open Science</i> , 2021 , 34, 17-18 | 0.9 | 1 |
| 12 | LBA-21 68GA-PSMA-11 PET/CT DETECTS PROSTATE CANCER AT EARLY BIOCHEMICAL RECURRENCE WITH SUPERIOR DETECTION RATE AND READER AGREEMENT WHEN COMPARED TO 18F-FLUCICLOVINE PET/CT IN A PROSPECTIVE HEAD-TO-HEAD COMPARATIVE PHASE 3 STUDY. <i>Journal of Urology</i> , 2019 , 201, | 2.5 | 1 |
| 11 | PET imaging in prostate cancer, state of the art: a review of 18F-choline and 11C-choline PET/CT applications. <i>Clinical and Translational Imaging</i> , 2016 , 4, 449-456 | 2 | 1 |
| 10 | Features and management of men with pN1 cM0 prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidence. <i>Current Opinion in Urology</i> , 2022 , 32, 69-84 | 2.8 | 0 |
| 9 | Radiation Therapy After Radical Prostatectomy: What Has Changed Over Time?. <i>Frontiers in Surgery</i> , 2021 , 8, 691473 | 2.3 | 0 |
| 8 | Integration of Targeted Gene Expression Profiling and FDG-PET Radiomics Uncovers Radiometabolic Signatures Associated with Outcome in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 3496-3496 | 2.2 | |
| 7 | Local and Systemic Staging by Modern Imaging Modalities in Prostate Cancer 2018 , 1-15 | | |
| 6 | Local and Systemic Staging by Modern Imaging Modalities in Prostate Cancer 2019 , 125-139 | | |
| 5 | Prospective head-to-head comparative phase 3 study between 18F-fluciclovine and 68Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5014-5014 | 2.2 | |
| 4 | PET/CT and Prostate Cancer 2016 , 57-64 | | |

3 New Radiopharmaceutical Markers for Metabolism and Receptor **2017**, 95-104

2 **18F-Choline, 68Ga-PSMA-11 and 18F-FDG PET/CT in Treatment Response Evaluation: Prostate Cancer 2021, 261-295**

1 COVID-19 and Aspiration Pneumonia: Similar Pulmonary Findings with Different Diagnoses-a Pitfall in [18F]FDG PET/CT. *SN Comprehensive Clinical Medicine*, **2021**, 1-4

2.7